GSK sets aside $400M for possible settlement
Pharma Compliance Alert, February 4, 2009
GlaxoSmithKline (GSK) is preparing to settle an ongoing investigation into the company’s marketing and promotional practices for nine of its best-selling products between 1997 and 2004.
GSK announced in a January 29 press release that it was recording a legal charge of $400 million for the fourth quarter of 2008 in relation to the investigation.
Continue reading about GSK's possible $400 million settlement.
Comments
0 comments on “GSK sets aside $400M for possible settlement ”
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- What does case-mix index mean to you?
- HHS task force: Consider privacy, security with text messages
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Searched
